title: Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
abstract: We have designed a dual-aptamer complex specific to both prostate-specific membrane antigens (PSMA) (+) and (-) prostate cancer cells. In the complex, an A10 RNA aptamer targeting PSMA (+) cells and a DUP-1 peptide aptamer specific to PSMA (-) cells were conjugated through streptavidin. Doxorubicin-loaded onto the stem region of the A10 aptamer was delivered not only to PSMA (+) cells but to PSMA (-) cells, and eventually induced apoptosis in both types of prostate cancer cells. Cell death was monitored by measuring guanine concentration in cells using differential pulse voltammetry (DPV), a simple and rapid electrochemical method, and was further confirmed by directly observing cell morphologies cultured on the transparent indium tin oxide (ITO) glass electrode and checking their viabilities using a trypan blue assay. To investigate the in vivo application of the dual-aptamer system, both A10 and DUP-1 aptamers were immobilized on the surface of thermally cross-linked superparamagnetic iron oxide nanoparticles (TCL-SPION). Selective cell uptakes and effective drug delivery action of these probes were verified by Prussian blue staining and trypan blue staining, respectively.
authors.affiliation: Department of Chemistry, Pohang University of Science and Technology, San31, Hyoja-dong, Pohang, Gyungbuk 790-784, South Korea.
authors.forename: Kyoungin
authors.initials: K
authors.lastname: Min
authors.forename: Hunho
authors.initials: H
authors.lastname: Jo
authors.forename: Kyungmi
authors.initials: K
authors.lastname: Song
authors.forename: Minseon
authors.initials: M
authors.lastname: Cho
authors.forename: Yang-Sook
authors.initials: YS
authors.lastname: Chun
authors.forename: Sangyong
authors.initials: S
authors.lastname: Jon
authors.forename: Won Jong
authors.initials: WJ
authors.lastname: Kim
authors.forename: Changill
authors.initials: C
authors.lastname: Ban
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000954:Antigens, Surface / Q000235:genetics / Q000378:metabolism*; D052157:Aptamers, Nucleotide / Q000737:chemistry*; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods*; D043425:Glutamate Carboxypeptidase II / Q000235:genetics / Q000378:metabolism*; D006147:Guanine / Q000378:metabolism; D006367:HeLa Cells; D006801:Humans; D008297:Male; D008958:Models, Molecular; D010455:Peptides / Q000737:chemistry; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011487:Protein Conformation
chemical_list: D000903:Antibiotics, Antineoplastic; D000954:Antigens, Surface; D052157:Aptamers, Nucleotide; C501462:DUP-1 peptide; D010455:Peptides; D006147:Guanine; D004317:Doxorubicin; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II